Phase II clinical trial - Recherches "plusieurs pathologies"
STARTRK-2 - GO40782
Recherches "plusieurs pathologies"
Essai clinique fermé
Public cible
Adulte
A Phase 2, Multicenter, Open-Label Study of Entrectinib for the Treatment of Locally Advanced or Metastatic NSCLC in Adult Patients with Tumors That Harbor NTRK1, NTRK2, NTRK3 or ROS1 Molecular Alterations
Description de l'essai
This trial evaluated the efficacy of an NTRK inhibitor across tumor types in patients whose tumor harbor an NTRK translocation. These translocations are assessed at the Institut Curie from archival tissue.
Liens utiles
CHRISTOPHE LE TOURNEAU
Investigateur principal